Twist Bioscience
TWST
246 hedge funds and large institutions have $2.62B invested in Twist Bioscience in 2025 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 79 increasing their positions, 90 reducing their positions, and 51 closing their positions.
44% more call options, than puts
Call options by funds: $3.47M | Put options by funds: $2.41M
18% more capital inflows, than outflows
Capital inflows: $310M | Capital outflows: $262M
2.44% more ownership
Funds ownership: 111% → 113.44% (+2.4%)
6% less funds holding
Funds holding: 263 → 246 (-17)
12% less repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 90
27% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 51
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EdgePoint Investment Group
Toronto,
Ontario, Canada
|
+$44M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$25.1M |
| 3 |
BlackRock
New York
|
+$22.2M |
| 4 |
Goldman Sachs
New York
|
+$20.5M |
| 5 |
Morgan Stanley
New York
|
+$20.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
-$42.3M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$35.8M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$27.3M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$12.5M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
-$10.5M |
TWST Hedge Fund Activity: Q2 2025 in Review
246 of the 7,627 institutional investors tracked by Wall St. Rank reported a position in Twist Bioscience (TWST) for Q2 2025, worth a combined $2.62B — down 4.2% from $2.73B a quarter earlier.
Sellers outnumbered buyers: 51 funds closed out of TWST and 37 opened new positions — a net loss of 14 holders — while 90 trimmed existing stakes and 79 added.
The largest buyer was EdgePoint Investment Group, adding an estimated $44M. The largest seller was UBS AM, cutting an estimated $42.3M.
- 246 institutional investors held Twist Bioscience (TWST) as of Q2 2025, down from 263 in Q1 2025.
- Funds reported $2.62B of Twist Bioscience stock for Q2 2025, down 4.2% quarter-over-quarter.
- 37 funds opened new Twist Bioscience positions in Q2 2025 and 51 closed out, a net change of -14 holders.
- The largest Twist Bioscience buyer in Q2 2025 was EdgePoint Investment Group, an estimated $44M added.
- The largest Twist Bioscience seller in Q2 2025 was UBS AM, an estimated $42.3M sold.
Based on aggregated 13F filings for Q2 2025.